Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group
Citations Over TimeTop 10% of 2022 papers
Abstract
The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.
Related Papers
- → Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor?(2010)34 cited
- → Development of a Standing-Up Motion Guidance System Using an Inertial Sensor(2014)3 cited
- 학습과 진화의 라마키안 상호 적응에 의한 최적 COG 비퍼지화기 설계(2018)
- → The pre-cog within (and the intra-cog, and the post-cog)(2018)
- → Evaluation of the Postural Response to Backward Stress on a Narrow Platform(2023)